Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | ACHE | P22303 | 11/20 | 0.44 |
| ▸ | BACE1 | P56817 | 10/20 | 0.44 |
| ▸ | BCHE | P06276 | 7/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.41 |
| ▸ | CCR3 | P51677 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3022229 | 0.85 | CLPP (0.38) | MEN1KMT2AACHESIGMAR1 | |
| SCHEMBL3014592 | 0.80 | CYP19A1 (0.37) | MEN1KMT2ASIGMAR1ALDH1A1 | |
| SCHEMBL3010219 | 0.77 | CYP19A1 (0.39) | MEN1KMT2ASIGMAR1ALDH1A1 | |
| SCHEMBL3022050 | 0.74 | CYP19A1 (0.37) | MEN1KMT2ASIGMAR1ALDH1A1 | |
| SCHEMBL16515936 | 0.73 | CYP19A1 (0.42) | MEN1KMT2AACHESIGMAR1ALDH1A1 | |
| SCHEMBL3023355 | 0.67 | CYP11B1 (0.36) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3023245 | 0.67 | CYP11B1 (0.43) | SMN1; SMN2 | |
| SCHEMBL3023816 | 0.67 | CYP19A1 (0.35) | ACHEALDH1A1SMN1; SMN2 | |
| SCHEMBL3012557 | 0.67 | EGFR (0.35) | ACHEBCHEALDH1A1SMN1; SMN2 | |
| SCHEMBL7219006 | 0.64 | MEN1 (0.75) | MEN1KMT2AACHEBACE1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204212-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-12 | — | — | US | disclosed |
| US-7723336-B2 | Fused heterocyclic compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-05-25 | — | — | US | disclosed |
| US-20080045536-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204212-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | MAP2K2, MAP3K2, MAP4K2 | MEN1 1665/4885KMT2A 584/4885ACHE 3761/4885 |
| US-20080045536-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | MAP3K3, MAP3K2, MAP4K3 | MEN1 1632/4885KMT2A 726/4885ACHE 3779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.